Jaroslav Zak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaroslav Zak has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- John R. Teijaro
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA
39 shared publications - Isaraphorn Pratumchai
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California
32 shared publications - Brandon Dinner
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, California
30 shared publications - Evan W. Weber
Division of Oncology, Department of Pediatrics, The Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, USA
30 shared publications - Ke Qin
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, California
30 shared publications - Peng Wu
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, USA
30 shared publications
Latest Publications
- 12 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Launching an independent research laboratory and scientific career: Tools for a rapidly changing landscape
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.
- 12 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Launching an independent research laboratory and scientific career: Tools for a rapidly changing landscape
Scientific independence alone does not create a sustainable research program. Drawing on the 2026 Irving Cancer Immunology Symposium, we offer practical strategies for navigating uncertainty and limited resources to build a coherent research program and resilient team across funding systems.
- Open Access
An IL-34–IGF-1 inflammatory axis fuels KRAS-mutant lung cancer progression
Macrophages are innate immune cells of embryonic or adult origin with tissue specific roles in homeostasis, disease surveillance, and wound repair that can be co-opted to promote tumor growth and spread 1–11 . An understanding of the specific roles of macrophage subsets in lung tumor initiation and progression could promote new therapeutic approaches for this deadly disease. Here, we show that KRAS G12D mutations in lung epithelium drive proliferation of resident, embryonically-derived alveolar macrophages, which then promote tumor cell proliferation and protection from ferroptosis, leading to tumor progression. Using genetically engineered mouse models of mutant KRAS G12D non-small cell lung cancer 12,13 , we found that alveolar macrophages accumulate by proliferation in response to tumor cell-secreted IL-34, recapitulating events observed in late embryonic lung development. Tumor alveolar macrophages in turn drive IGF-1-dependent tumor cell proliferation. Neutralization or deletion of IL-34 suppresses IGF-1 expression, reduces macrophage and tumor cell proliferation and inhibits tumor progression. High IL34 and IGF1 correlate with poor survival in KRAS G12D/V lung adenocarcinomas and in other solid tumors, indicating that bi-directional proliferative signaling between resident macrophages and tumor cells can drive human lung tumor progression. These studies identify resident macrophage-tumor cell interactions as key interception points for lung cancer therapy.
Open AccessAn IL-34–IGF-1 inflammatory axis fuels KRAS-mutant lung cancer progression
Macrophages are innate immune cells of embryonic or adult origin with tissue specific roles in homeostasis, disease surveillance, and wound repair that can be co-opted to promote tumor growth and spread 1–11 . An understanding of the specific roles of macrophage subsets in lung tumor initiation and progression could promote new therapeutic approaches for this deadly disease. Here, we show that KRAS G12D mutations in lung epithelium drive proliferation of resident, embryonically-derived alveolar macrophages, which then promote tumor cell proliferation and protection from ferroptosis, leading to tumor progression. Using genetically engineered mouse models of mutant KRAS G12D non-small cell lung cancer 12,13 , we found that alveolar macrophages accumulate by proliferation in response to tumor cell-secreted IL-34, recapitulating events observed in late embryonic lung development. Tumor alveolar macrophages in turn drive IGF-1-dependent tumor cell proliferation. Neutralization or deletion of IL-34 suppresses IGF-1 expression, reduces macrophage and tumor cell proliferation and inhibits tumor progression. High IL34 and IGF1 correlate with poor survival in KRAS G12D/V lung adenocarcinomas and in other solid tumors, indicating that bi-directional proliferative signaling between resident macrophages and tumor cells can drive human lung tumor progression. These studies identify resident macrophage-tumor cell interactions as key interception points for lung cancer therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S6 EZH2 inhibition by tazemetostat during in vitro expansion enhanced in vivo response of OT-I cells upon LM-OVA infection and improved long-term survival of OT-I cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S6 EZH2 inhibition by tazemetostat during in vitro expansion enhanced in vivo response of OT-I cells upon LM-OVA infection and improved long-term survival of OT-I cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S2. Induction of EZH2 expression during human T cell stimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S2. Induction of EZH2 expression during human T cell stimulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S1 Expression level of EZH2 in public datasets and Phenotypic analysis of effector and exhausted OT-I T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S1 Expression level of EZH2 in public datasets and Phenotypic analysis of effector and exhausted OT-I T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S14 Phenotype and cytokine expression analysis of HA-28z CAR-T cells treated with vehicle or tazemeostat before (A-B) or after (C-D) a re-stimulation for 3 days. 3 repeats for each group (n=3), nsP > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; analyzed by Student’s t-test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S14 Phenotype and cytokine expression analysis of HA-28z CAR-T cells treated with vehicle or tazemeostat before (A-B) or after (C-D) a re-stimulation for 3 days. 3 repeats for each group (n=3), nsP > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; analyzed by Student’s t-test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S4 OT-I splenocytes were stimulated with 500 nM OVA257-264 for 3 days in the presence of 60 IU/mL IL2 and analyzed on day3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S4 OT-I splenocytes were stimulated with 500 nM OVA257-264 for 3 days in the presence of 60 IU/mL IL2 and analyzed on day3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S7 Phenotype and cytokine expression analysis of OT-I cells in LM-OVA infection model
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S7 Phenotype and cytokine expression analysis of OT-I cells in LM-OVA infection model
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.